NEWS WRAP: Hutchmed sells non-core asset to focus on cancer treatment
The drug maker is selling most of its stake in a joint venture with Shanghai Pharmaceuticals for $608 million By Teri Yu Hutchmed (China) Ltd. (HCM.US; 0013.HK; HCM.L), the biopharmaceutical…
Inmagene Bio charts backdoor to U.S. listing with offshore acquisition
The biotech company’s merger with Ikena Oncology will bring in $175 million in fresh funds, including $75 million from an oversubscribed private placement Key Takeaways: Inmagene Bio plans to merge…
Hutchmed scores U.S. success with cancer drug, but profits still dip
The drug developer has reported sharply reduced profits, coming off an exceptionally high base last year, but sales of its key cancer medicine are accelerating in the United States Key…
FAST NEWS: Hutchmed swings to profit on strong revenue growth
The latest: Hutchmed (China) Ltd. (HCM.US; 0013.HK) announced Monday a net profit of $169 million in the first half of 2023, reversing a loss of $163 million in the same period…
FAST NEWS: Hutchmed Sells Cancer Drug’s Overseas Rights for up to $1.13 Billion
The latest: Hutchmed (China) Ltd. (HCM.US; 0013.HK) announced on Wednesday that it has exclusively licensed Japan’s Takeda Pharmaceutical (TAK.US; 4502.T) to develop, manufacture and sell its metastatic colorectal cancer drug…
FAST NEWS: Hutchmed, Zai Lab, Ascentage Drugs Land on China Reimbursement List
The latest: Products from Hutchmed (China) Ltd. (HCM.US; 0013.HK), Zai Lab Ltd. (ZLAB.US; 9688.HK) and Ascentage Pharma Group (6855.HK) were among 111 new drugs selected for new inclusion in the…
FAST NEWS: Hutchmed Receives Additional Holdings from U.S. Fund
The latest: The Capital Group Companies, Inc., a U.S.-based fund disclosed it purchased 1.285 million shares in Hutchmed (China) Ltd. (HCM.US; 0013.HK) for HK$22.14 million ($2.84 million), raising its stake…